The coming of age of microRNA for B cell lymphomas

Histopathology

Volumn 58, Issue 1, 2011, Pages 39-48

  Auer, Rebecca L ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Lymphoma; MicroRNAs; Normal B cells

Indexed keywords

IMMUNOGLOBULIN G1; INTERLEUKIN 10; MICRORNA; MIR 155; PROTEIN BCL 2; RNA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HUMAN; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; LYMPHOCYTE; MANTLE CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE;

B-LYMPHOCYTES; GENOME, HUMAN; HUMANS; LYMPHOMA, B-CELL; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 78851472385     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03698.x     Document Type: Review

References (73)

1. Miska EA. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev. 2005; 15; 563-568.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116; 281-297.
3. Ambros V, Chen X. The regulation of genes and genomes by small RNAs. Development 2007; 134; 1635-1641.
4. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115; 787-798.
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120; 15-20.
6. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75; 855-862.
7. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75; 843-854.
8. Reinhart BJ, Slack FJ, Basson M et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403; 901-906.
9. Pasquinelli AE, Reinhart BJ, Slack F et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000; 408; 86-89.
10. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001; 294; 862-864.
11. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006; 34; D140-D144.
12. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 2005; 6; 376-385.
13. Olive V, Bennett MJ, Walker JC et al. mir-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009; 23; 2839-2849.
14. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 2002; 99; 15524-15529.
15. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 2004; 101; 2999-3004.
16. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435; 834-838.
17. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303; 83-86.
18. Zhang J, Jima DD, Jacobs C et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009; 113; 4586-4594.
19. Basso K, Sumazin P, Morozov P et al. Identification of the human mature B cell miRNome. Immunity 2009; 30; 744-752.
20. Malumbres R, Sarosiek KA, Cubedo E et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009; 113; 3754-3764.
21. Tan LP, Wang M, Robertus JL et al. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab. Invest. 2009; 89; 708-716.
22. Landgraf P, Rusu M, Sheridan R et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129; 1401-1414.
23. Monticelli S, Ansel KM, Xiao C et al. MicroRNA profiling of the murine hematopoietic system. Genome Biol. 2005; 6; R71.
24. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc. Natl Acad. Sci. USA 2007; 104; 7080-7085.
25. Xiao C, Calado DP, Galler G et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007; 131; 146-159.
26. Ventura A, Young AG, Winslow MM et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132; 875-886.
27. Xiao C, Srinivasan L, Calado DP et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 2008; 9; 405-414.
28. He L, He X, Lim LP et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447; 1130-1134.
29. Chang TC, Wentzel EA, Kent OA et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007; 26; 745-752.
30. Rao DS, O'Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 2010; 33; 48-59
31. Koralov SB, Muljo SA, Galler GR et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008; 132; 860-874.
32. Eis PS, Tam W, Sun L et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl Acad. Sci. USA 2005; 102; 3627-3632.
33. Kluiver J, Poppema S, de Jong D et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J. Pathol. 2005; 207; 243-249.
34. Georgantas RW III, Hildreth R, Morisot S et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc. Natl Acad. Sci. USA 2007; 104; 2750-2755.
35. van den Berg A, Kroesen BJ, Kooistra K et al. High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosom. Cancer 2003; 37; 20-28.
36. Rodriguez A, Vigorito E, Clare S et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316; 608-611.
37. Thai TH, Calado DP, Casola S et al. Regulation of the germinal center response by microRNA-155. Science 2007; 316; 604-608.
38. Vigorito E, Perks KL, Abreu-Goodger C et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007; 27; 847-859.
39. Dorsett Y, McBride KM, Jankovic M et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 2008; 28; 630-638.
40. Teng G, Hakimpour P, Landgraf P et al. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 2008; 28; 621-629.
41. Cimmino A, Calin GA, Fabbri M et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 2005; 102; 13944-13949.
42. Fulci V, Chiaretti S, Goldoni M et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109; 4944-4951.
43. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res. 2008; 68; 1012-1021.
44. Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA 2004; 101; 11755-11760.
45. Calin GA, Ferracin M, Cimmino A et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005; 353; 1793-1801.
46. Stamatopoulos B, Meuleman N, Haibe-Kains B et al. MicroRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009; 113; 5237-5245.
47. Klein U, Lia M, Crespo M et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17; 28-40.
48. Zenz T, Mohr J, Eldering E et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009; 113; 3801-3808.
49. Mraz M, Malinova K, Kotaskova J et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 2009; 23; 1159-1163.
50. Zenz T, Habe S, Denzel T et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114; 2589-2597.
51. Dijkstra MK, van Lom K, Tielemans D et al. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia 2009; 23; 625-627.
52. Visone R, Rassenti LZ, Veronese A et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114; 3872-3879.
53. Asslaber D, Pinon JD, Seyfried I et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 2010; 115; 4191-4197.
54. Rossi S, Shimizu M, Barbarotto E et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010; 116:945-952.
55. Merkel O, Asslaber D, Pinon JD, Egle A, Greil R. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle 2010; 9; 2764-2768.
56. Moussay E, Palissot V, Vallar L et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol. Cancer 2010; 9; 115.
57. Ferreira BI, Garcia JF, Suela J et al. Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica 2008; 93; 670-679.
58. Costinean S, Zanesi N, Pekarsky Y et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc. Natl Acad. Sci. USA 2006; 103; 7024-7029.
59. O'Connell RM, Rao DS, Chaudhuri AA et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J. Exp. Med. 2008; 205; 585-594.
60. Roehle A, Hoefig KP, Repsilber D et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br. J. Haematol. 2008; 142; 732-744.
61. Pedersen IM, Otero D, Kao E et al. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol. Med. 2009; 1; 288-295.
62. Lawrie CH, Soneji S, Marafioti T et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int. J. Cancer 2007; 121; 1156-1161.
63. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc. Natl Acad. Sci. USA 2010; 107; 3111-3116.
64. Lenz G, Wright GW, Emre NC et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl Acad. Sci. USA 2008; 105; 13520-13525.
65. Ota A, Tagawa H, Karnan S et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004; 64; 3087-3095.
66. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression Nature 2005; 435; 839-843.
67. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009; 113; 396-402.
68. Li C, Kim SW, Rai D et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 2009; 113; 6681-6690.
69. Chen RW, Bemis LT, Amato CM et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 2008; 112; 822-829.
70. Wiestner A, Tehrani M, Chiorazzi M et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007; 109; 4599-4606.
71. Navarro A, Bea S, Fernandez V et al. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res. 2009; 69; 7071-7078.
72. Zhao JJ, Lin J, Lwin T et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115; 2630-2639.
73. Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008; 141; 672-675.